155 related articles for article (PubMed ID: 17949785)
1. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
2. Mucin 1-mediated chemo-resistance in lung cancer cells.
Ham SY; Kwon T; Bak Y; Yu JH; Hong J; Lee SK; Yu DY; Yoon DY
Oncogenesis; 2016 Jan; 5(1):e185. PubMed ID: 26779808
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
[TBL] [Abstract][Full Text] [Related]
4. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
Yeh P; Chen H; Andrews J; Naser R; Pao W; Horn L
Clin Cancer Res; 2013 Apr; 19(7):1894-901. PubMed ID: 23344264
[TBL] [Abstract][Full Text] [Related]
5. WNT signalling pathways as therapeutic targets in cancer.
Anastas JN; Moon RT
Nat Rev Cancer; 2013 Jan; 13(1):11-26. PubMed ID: 23258168
[TBL] [Abstract][Full Text] [Related]
6. Targeting mutant p53 in human tumors.
Lehmann BD; Pietenpol JA
J Clin Oncol; 2012 Oct; 30(29):3648-50. PubMed ID: 22965952
[No Abstract] [Full Text] [Related]
7. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
Ma C; Wei S; Song Y
J Thorac Dis; 2011 Mar; 3(1):10-8. PubMed ID: 22263058
[TBL] [Abstract][Full Text] [Related]
8. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
[TBL] [Abstract][Full Text] [Related]
9. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
Di Nicolantonio F; Arena S; Tabernero J; Grosso S; Molinari F; Macarulla T; Russo M; Cancelliere C; Zecchin D; Mazzucchelli L; Sasazuki T; Shirasawa S; Geuna M; Frattini M; Baselga J; Gallicchio M; Biffo S; Bardelli A
J Clin Invest; 2010 Aug; 120(8):2858-66. PubMed ID: 20664172
[TBL] [Abstract][Full Text] [Related]
11. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Sos ML; Koker M; Weir BA; Heynck S; Rabinovsky R; Zander T; Seeger JM; Weiss J; Fischer F; Frommolt P; Michel K; Peifer M; Mermel C; Girard L; Peyton M; Gazdar AF; Minna JD; Garraway LA; Kashkar H; Pao W; Meyerson M; Thomas RK
Cancer Res; 2009 Apr; 69(8):3256-61. PubMed ID: 19351834
[TBL] [Abstract][Full Text] [Related]
12. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.
Groen RW; Oud ME; Schilder-Tol EJ; Overdijk MB; ten Berge D; Nusse R; Spaargaren M; Pals ST
Cancer Res; 2008 Sep; 68(17):6969-77. PubMed ID: 18757411
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.
Waqar SN; Baggstrom MQ; Morgensztern D; Williams K; Rigden C; Govindan R
Chemotherapy; 2016; 61(3):144-7. PubMed ID: 26780363
[TBL] [Abstract][Full Text] [Related]
14. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.
Lehmann S; Bykov VJ; Ali D; Andrén O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson PO
J Clin Oncol; 2012 Oct; 30(29):3633-9. PubMed ID: 22965953
[TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
16. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
Barton KL; Misuraca K; Cordero F; Dobrikova E; Min HD; Gromeier M; Kirsch DG; Becher OJ
PLoS One; 2013; 8(10):e77639. PubMed ID: 24098593
[TBL] [Abstract][Full Text] [Related]
17. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
[TBL] [Abstract][Full Text] [Related]
18. Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.
Calhoun S; Daggett V
Biochemistry; 2011 Jun; 50(23):5345-53. PubMed ID: 21561095
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B; Warne PH; Downward J
Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients.
Betticher DC; Heighway J; Thatcher N; Hasleton PS
Br J Cancer; 1997; 75(12):1761-8. PubMed ID: 9192978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
